Lujan, M.

screening cancer prostate cancer prostate group study control treatment death erspc control arm mortality control group contamination analysis trial screening group european effect screening arm result subject european randomised study schr öder fh study arm urology center value european randomized study reduction randomized nonattendance randomised cohort treatment choice rotterdam department university centre number difference roobol analyses koning hj table biopsy mortality reduction men randomised stage pca deaths nejm.org testing choice randomization control subject antigen psa test screen prostate-cancer hospital ratio medicine downloaded follow-up pc cases england journal tumor 69 years schroder erasmus university distribution randomisation adjustment committee roobol mj finland erspc rotterdam psa testing psa value core age group prostate cancer screening